Sarbecovirus

New Publications Confirm Paragon Genomics CleanPlex® SARS-CoV-2 Panel Enables Accurate Identification of Variants of Concern

Retrieved on: 
Wednesday, July 28, 2021

The analyses enabled the researchers to assign the viral genomes to SARS-CoV-2 lineages and confirm the presence of the B.1.1.7 variant.

Key Points: 
  • The analyses enabled the researchers to assign the viral genomes to SARS-CoV-2 lineages and confirm the presence of the B.1.1.7 variant.
  • A third study, from a Paragon Genomics public health laboratory customer, describes how the CleanPlex SARS-CoV-2 Panel enabled the early identification of one of the first confirmed cases of the B.1.617.2 Delta variant in Brazil.
  • Paragon Genomics' CleanPlex SARS-CoV-2 technology has powered variant detection and tracking since the virus first appeared.
  • In March 2020, the company launched the CleanPlex SARS-CoV-2 Panel whole genome SARS-CoV-2 sequencing on Illumina and MGI Tech sequencing platforms.

Vertosa Announces U.S. Patent, Engages Emery Pharma for Research That Applies Their Pharmaceutical Development Expertise to Cannabis-Infused Products

Retrieved on: 
Tuesday, July 27, 2021

Founded in 2018, Vertosa is a science-first cannabis company that creates the most effective and reliable active ingredients for infused products.

Key Points: 
  • Founded in 2018, Vertosa is a science-first cannabis company that creates the most effective and reliable active ingredients for infused products.
  • The team at Emery Pharma is skilled in Method Development and Validation, Characterization and Isolation of impurities, Stability Studies, and Release Testing.
  • Emery Pharma also develops methods and procedures in support of patent litigation , intellectual property, drug recalls, and product liability cases.
  • Since March 2020, Emery Pharma has engaged in development of a Sars-CoV-2 surrogate betacoronavirus assay for antiviral efficacy testing.

VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant

Retrieved on: 
Tuesday, July 27, 2021

New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure

Key Points: 
  • New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure
    SPL7013, the antiviral agent in VIRALEZE, has now been shown in laboratory studies to be virucidal against all four coronavirus SARS-CoV-2 Variants of Concern: Alpha, Beta, Gamma and Delta
    These latest data further illustrate the broad-spectrum antiviral activity of SPL7013, which has been demonstrated against multiple respiratory viruses, including influenza and RSV, as well as its consistent and potent activity against multiple SARS-CoV-2 variants
    VIRALEZE antiviral nasal spray is registered for sale in Europe and India, and available in certain markets online.
  • MELBOURNE, Australia, July 27, 2021 /PRNewswire/-- Starpharma today announced new data demonstrating that SPL7013, the antiviral agent in VIRALEZE nasal spray, is active against the highly transmissible Delta variant of SARS-CoV-2, achieving more than 99.99% reduction of infectious virus in laboratory-based virucidal assays.
  • The antiviral testing of SPL7013 was conducted in the laboratory of virologist, Professor Philippe Gallay, atThe Scripps Research Institute in the US, where previous studies have also demonstrated potent antiviral and virucidal activity of SPL7013 against multiple variants of SARS-CoV-2, including the globally important Alpha, Beta and Gamma 'Variants of Concern'.
  • Percent reductions of infectious virus achieved with 10 mg/mL SPL7013 (the concentration in VIRALEZE) are shown in the table below.

Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines

Retrieved on: 
Tuesday, July 27, 2021

Oragenics, Inc. (NYSE American: OGEN) today announced it has entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) today announced it has entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.
  • The NRC technologies, developed with support from the NRCs Pandemic Response Challenge Program, will expedite the evaluation of SARS-CoV-2 antigen candidates in preclinical and clinical studies.
  • Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms.
  • Its lantibiotics program features a novel class of antibiotics against infectious diseases that have developed resistance to commercial antibiotics.

Ondine Biomedical to present results on the effects of its upper airways decolonization technology for SARS-CoV-2 eradication at ICPIC 2021

Retrieved on: 
Monday, July 26, 2021

Canadian medical technology innovator, Ondine Biomedical, will be presenting results from a successful in vitro study of its pioneering Steriwave upper airway disinfection technology against SARS-CoV-2 at the International Conference on Prevention and Infection Control (ICPIC) in Geneva, on 15th September 2021.

Key Points: 
  • Canadian medical technology innovator, Ondine Biomedical, will be presenting results from a successful in vitro study of its pioneering Steriwave upper airway disinfection technology against SARS-CoV-2 at the International Conference on Prevention and Infection Control (ICPIC) in Geneva, on 15th September 2021.
  • The presentation will focus on results demonstrating that this patented photodisinfection therapy can rapidly destroy the RNA genome of SARS-CoV-2.
  • The nose and upper airway have been identified as ideal breeding grounds and reservoirs for many threatening pathogens including MRSA, Candida auris, and SARS-Cov-2.
  • Ondines Steriwave photodisinfection therapy can rapidly and painlessly eradicate pathogens in the nose and upper airway, helping to eliminate a leading source of infection and transmissions.

SpeeDx Launch Solution for SARS-CoV-2 Variant Analysis

Retrieved on: 
Monday, July 26, 2021

Ltd., a developer of innovative molecular diagnostic solutions, have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of concern (VOC).

Key Points: 
  • Ltd., a developer of innovative molecular diagnostic solutions, have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of concern (VOC).
  • Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe.
  • SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management.
  • For more information on SpeeDx please see: https://plexpcr.com
    SARS-CoV-2 Variant Classifications and Definitions.

JBS Couros launches antiviral leather

Retrieved on: 
Thursday, July 22, 2021

SÃO PAULO, July 22, 2021 /PRNewswire/ -- JBS Couros has announced the launch of JBS V-Block technology, which inactivates the SARS-Cov-2 virus, the cause of Covid-19. At processing stage, a silver microparticle additive is added to the leather coating   providing it with antiviral qualities.

Key Points: 
  • SO PAULO, July 22, 2021 /PRNewswire/ --JBS Couros has announced the launch of JBS V-Block technology, which inactivates the SARS-Cov-2 virus, the cause of Covid-19.
  • At processing stage, a silver microparticle additive is added to the leather coating providing it with antiviral qualities.
  • "Our leather has undergone scientific tests that prove the inactivation of the SARS-Cov-2 virus.
  • "The use of this technology increases the contact surface of silver and its prominence in the leather, enabling antiviral action," says researcher Lucio Freitas, who participated in the tests of the new material.

Delta Variant Infections of COVID Rising Quickly & Now Responsible for 83% of All U.S. Cases

Retrieved on: 
Thursday, July 22, 2021

They found that one key player in the immune response to SARS-CoV-2the CD8+ T cellremained active against the virus."

Key Points: 
  • They found that one key player in the immune response to SARS-CoV-2the CD8+ T cellremained active against the virus."
  • Each variant has mutations throughout the virus, and, in particular, in the region of the virus' spike protein that it uses to attach to and enter cells.
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.
  • The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Delta Variant Infections of COVID Rising Quickly & Now Responsible for 83% of All U.S. Cases

Retrieved on: 
Thursday, July 22, 2021

PALM BEACH, Fla., July 22, 2021 /PRNewswire/ -- According to WebMD, this week the nation's top health officials said Tuesday that the Delta variant of the coronavirus is racing through North America and other parts of the world and now is responsible for 83% of all U.S. cases alone. That's a massive increase from a week ago, when Delta was seen as responsible for just more than half of new cases, CDC Director Rochelle Walensky, MD, told a Senate committee. "The best way to prevent the spread of COVID-19 variants is to prevent the spread of disease, and vaccination is the most powerful tool we have," she said. Meanwhile, several states in the South are reporting a large increase in COVID-19 cases, particularly in areas with low vaccination rates, according to The Atlanta Journal-Constitution. Arkansas, Florida, and Missouri are reporting full-fledged outbreaks, and neighboring states such as Alabama, Georgia, Louisiana, Mississippi, Tennessee, and Texas are following behind. According to the National Institutes of Health (NIH): "When variants of SARS-CoV-2 (the virus that causes COVID-19) emerged in late 2020, concern arose that they might elude protective immune responses generated by prior infection or vaccination, potentially making re-infection more likely or vaccination less effective. To investigate this possibility, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and colleagues analyzed blood cell samples from 30 people who had contracted and recovered from COVID-19 prior to the emergence of virus variants. They found that one key player in the immune response to SARS-CoV-2—the CD8+ T cell—remained active against the virus."  Active biotech companies in the market this week include BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), Moderna, Inc. (NASDAQ: MRNA), Sorrento Therapeutics, Inc. (NASDAQ: SRNE).

Key Points: 
  • They found that one key player in the immune response to SARS-CoV-2the CD8+ T cellremained active against the virus."
  • Each variant has mutations throughout the virus, and, in particular, in the region of the virus' spike protein that it uses to attach to and enter cells.
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.
  • The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Daily™ Including 3CL Protease Inhibitor Claim

Retrieved on: 
Thursday, July 22, 2021

The Certificate of Free Sale is for a twice-daily dosing regimen and, critically, a 3CL protease inhibitor claim.

Key Points: 
  • The Certificate of Free Sale is for a twice-daily dosing regimen and, critically, a 3CL protease inhibitor claim.
  • The Company intends to establish a monthly subscription model as part of its marketing launch campaign for Tollovid Daily immune system support.
  • Tollovid and Tollovid Daily are both 3CL protease inhibitor products developed under a joint venture with NLC Pharma.
  • We are very excited with the new FDA Certificate of Free Sale for Tollovid Daily, the newest member of our Tollovid dietary supplement product line, said Gerald E. Commissiong, President & CEO of Todos Medical.